No pressure right! Debating Robert Z. Orlowski

Thanks Gurbakhash Kaur for the amazing kebabs delivered since she couldn’t take me out while in Dallas, the sweetest 🥹🫠

Imp manuscript from the Mayo group Saurabh Zanwar showing the outcomes of pts w/ suboptimal response to DaraVCd in NDAL. I have traditionally switched to BCL2 inhibition ASAP if t(11;14) but for the rest such a tricky spot! Hopeful for TCE in this popn

nature.com/articles/s4137…

Wonderful morning discussing the importance of MRD in high risk MM especially on the heels of the ODAC

Always great to listen to my previous co-fellow Urvi Shah talk passionately about nutrition and myeloma

Excellent thread on cilta-cel, only point I would highlight is if you progress on bridging therapy, your risk of fatal outcome 🔝 and in that situation I would not proceed directly with cilta cel but consider other options to lower disease burden!

When we presented this at EHA, less apparent but important to await data from additional patients and f/u at RP2D

Encouraging early data showing IMiDs and possibly CelMODs can improve on the response to immunotherapy Jeffrey Matous, MD Luciano J Costa

Glorious skies, thick crowds and ready for ASH Run

Applaud the massive effort Mike Thompson, MD, PhD, FASCO undertakes every year to give us a glimpse of the best of #mmsm at ASH and grateful to be included on this list!

So many things to be grateful for but most thankful this year for my lil turkey!
Happy Thanksgiving to all

An impassioned talk by the eloquent Sagar Lonial MD about how to get to CURE using available immunotherapies

More treatment to get to MRD negativity was also a feature for MRD resurgence/PD in the MASTER study - final paper in press Luciano J Costa Bruno Paiva

Excited to listen to Siddhartha Mukherjee in the fireside chat with Vincent Rajkumar Sagar Lonial MD about some upcoming first-in-class CART in myeloma developed by Dr. Mukherjee with our Indian colleagues

Join us Oct 19 for the Society for Immunotherapy of Cancer #LearnACI live virtual Hematologic Malignancies program featuring in-depth education re:immunotherapy for hematologic malignancies. Register/invite sitcancer.org/education/aci/…<urldefense.com/v3/__https://w…$> Rahul Banerjee, MD, FACP Urvi Shah Amer Zeidan MBBS,MHS ‏عامر زيدان

Fantastic news for our patients - First GPRC5D directed therapy approved. Several others in the making. Thanks Janssen for combining the REMS program with Tec! prnewswire.com/news-releases/…

The most wholesome content I saw this morning

Outstanding final results of first-in-concept trial of MRD adapted treatment modulation! Look forward to improving the outcomes of this problem subgroup with novel approaches in MASTER2 Luciano J Costa Binod Dhakal Smit Giri MD MHS Bhagirath Dholaria, MD Timothy Schmidt, MD Meera Mohan Raj Chakraborty